Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.
Secondary Hyperparathyroidism
DRUG: KHK7580
Number and types of adverse events, The safety of KHK7580 assessed by number and types of adverse events, laboratory tests, vital signs and electrocardiogram, For 8 days
Profiles of pharmacokinetics, intact parathyroid hormone, whole parathyroid hormone, corrected serum calcium, phosphorus, intact fibroblast growth factor 23, ionized calcium, calcitonin, Pre-dose, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 168 hours post-dose
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single administration of KHK7580 for secondary hyperparathyroidism in patients receiving peritoneal dialysis.